Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of pralsetinib versus standard first-line therapy in RET fusion-positive metastatic non-small cell lung cancer
MOH_2020-10-29_009457Phase 3Not yet recruiting
- Sponsor
- Blueprint Medicines
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pralsetinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Blueprint Medicines. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
pralsetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2020-10-29_009457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-10-29_009457.